This patent is part of Immunex's wall of IP surrounding the stem cell stimulatory cytokine flt3 ligand.
This patent covers the stimulation of hematopoietic stem cells with flt-3 ligand. This cytokine is used in many stem cell stimulation/expansion cocktails...additionally flt-3 ligand is one of the few cytokines that can preferentially induce expansion of tissue dendritic cells.
Hematopoietic stem cells are sensitive to chemotherapy and radiation therapy. Accordingly, hematopoietic stem cells are one of the first cell types to be negatively affected by cancer therapy. One of the reasons that hematopoietic stem cells are destroyed is due to the fact that at some level, they are proliferating constantly. Now, the early primitive hematopoietic stem cells usually...
This patent provides peptides that inhibit stem cell proliferation, specific inhibition of hematopoietic stem cell proliferation is covered. These peptides are originally derived from bone marrow, but here are generated synthetically. They are useful for protection of the bone marrow stem cell compartment from agents that kill mitotically active cells.
This patent covers a strange composition generated from bone marrow by various chemical and physical procedures that seems to inhibit leukemic stem cell proliferation. This patent is similar to a composition published previously called Reptimed that was also bone marrow derived and inhibited leukemic cell activity.
This patent covers peptides that inhibit proliferation of hematopoietic stem cells. These peptides may be used for protection form chemotherapy or radiotherapy induced stem cell destruction.
This patent teaches that inhibition of stem cell proliferation, and induction of differentiation may be achieved by inhibiting expression or function of the protein insulin like growth factor. This patent can also be used with more modern gene silencing techniques such as RNA interference.
This invention covers a composition of matter consisting of polypeptides that inhibit stem cell proliferation. This invention is useful for protecting stem cells during administration of chemotherapy or radiotherapy.
Specific bioreactors and culture conditions are provided for the expansion of hematopoietic stem cells. These cells may be used directly for treatment post marrow ablation, or may be further differentiated into specific hematological cells for treatment of specific diseases.
This patent provides analogues of chemokines that are capable of inhibiting proliferation of hematopoietic stem cells.